论文部分内容阅读
目的了解2型糖尿病(T2DM)患者治疗前后血清内脏脂肪素(Visfatin)水平的变化及其与炎症因子的关系。方法选取T2DM患者44例,用胰岛素泵强化治疗12～15d,同时给予调脂、降压等综合治疗。记录人体测量参数。监测治疗前后生化指标及空腹血清Visfatin、肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)的变化。结果治疗后血清Visfatin水平由(10.62±2.44)μg/L降至(8.38±1.72)μg/L,差异有统计学意义(P<0.01)。Pearson相关分析显示,治疗后血清Visfatin的下降值与WC、WHR以及TG、LDL-C、FBG、hsC-RP、TNF-α和IL-6的下降值呈正相关。多元逐步回归分析显示,WHR是影响Visfatin下降的独立相关因素。结论 T2DM患者治疗后血清Visfatin水平较治疗前显著下降,且与其他血清炎症因子的下降正相关,提示Visfatin可能在T2DM的发生发展中起重要作用。
Objective To investigate the changes of serum visfatin level and its relationship with inflammatory factors in type 2 diabetic patients before and after treatment. Methods Twenty-four patients with T2DM were selected and treated with insulin pump for 12-15 days. At the same time, they were given lipid-lowering and antihypertensive treatment. Record body measurement parameters. The changes of biochemical indexes and fasting serum visfatin, tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) were observed before and after treatment. Results After treatment, the level of Visfatin decreased from (10.62 ± 2.44) μg / L to (8.38 ± 1.72) μg / L, the difference was statistically significant (P <0.01). Pearson correlation analysis showed that the decline of serum Visfatin after treatment was positively correlated with the decrease of WC, WHR and TG, LDL-C, FBG, hsC-RP, TNF-α and IL-6. Multivariate stepwise regression analysis showed that WHR was an independent factor influencing Visfatin decline. Conclusions Visfatin levels in T2DM patients after treatment are significantly lower than those before treatment, and positively correlated with the decline of other serum inflammatory factors, suggesting that Visfatin may play an important role in the occurrence and development of T2DM.